Medical innovation is accelerating, yet the path from discovery to approved treatment remains slow and resource-intensive. For many patients, that delay matters. Researchers are now exploring whether ...
The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing (NGS) methods in nonclinical studies to assess the safety risks associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results